

Anti-VEGFR2/KDR/CD309 Antibody (Ramucirumab)

Introduction

Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist with anti-solid tumor effects. Ramucirumab (anti-VEGFR) is a human monoclonal antibody that binds to VEGFR-2 and prevents the binding of VEGFR ligands VEGF-A, VEGF-C and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor.

Product parameters

Alternative Names	Ramucirumab
Target Accession	P35968
Target	VEGFR2 / KDR / CD309
CAS number	947687-13-0
Molecular Weight	143.8 kDa
Host	CHO
Reactivity	Human, Cynomolgus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human VGFR2 His at 4 ug/mL can bind Anti-VEGFR2/KDR/CD309 Antibody (Ramucirumab), EC50=0.007088 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

